Risk of recurrence is routinely assessed by clinicians to understand prognosis and direct treatment decisions for each patient diagnosed with eBC. | my.novartis.be

Skip to main content

English
- Nederlands
- Français

Pin Code

If you have been supplied with a PIN Code, you may enter it here.

Leave this field blank

Sign In

Search Results

Therapeutic areas
Congresses & Events
- Cardiology
  - BSC
  - ESC
- Dermatology
  - EADV
  - Sharing is Caring
- Hematology
  - ASH
  - EHA
  - ESH
- Neurology
  - CMSC
  - EAN
  - ECTRIMS
- Oncology
  - ASCO
  - ESMO
  - EBCC
  - SABCS
- Rheumatology
  - Sharing is Caring
Contact

Popular Search

improved
improving
aimovig
migration
migraine

Recent News

Netelroos - Doe the test

Urticaire - Faire le test

Behandelingen Netelroos

Search

ebc11.png

Risk of recurrence is routinely assessed by clinicians to understand prognosis and direct treatment decisions for each patient diagnosed with eBC.

×

Ask the speakers

Toolbox

Contact

Novartis Pharma NV/SA: + 32 (0)2 246 16 11

Medical questions:

In case of an adverse event:

[email protected]
Phone number 24/h:
Bel: 0800 94 368
Lux: + 32 475 319 792

Toolbox Collapse

Subscribe to Novartis

Facebook
Instagram
LinkedIn
Twitter
YouTube

Cookie Settings

©2024 Novartis Belgium and Luxembourg

Terms of use
Privacy Policy
About cookies

This website is intended for health care professionals in Belgium and Luxembourg